Sebastian M Heimann
Overview
Explore the profile of Sebastian M Heimann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
82
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Heimann S, Penack O, Heinz W, Rachow T, Egerer G, Kessel J, et al.
Int J Infect Dis
. 2019 Apr;
83:130-138.
PMID: 30978465
Objectives: Novel formulations (gastro-resistant tablet and intravenous solution) of posaconazole (POS) have been approved in prophylaxis and therapy of invasive fungal diseases (IFDs). Study aim was to analyze treatment strategies...
2.
Zoran T, Sartori B, Sappl L, Aigner M, Sanchez-Reus F, Rezusta A, et al.
Front Microbiol
. 2019 Jan;
9:3245.
PMID: 30692970
[This corrects the article DOI: 10.3389/fmicb.2018.00516.].
3.
Wilke M, Becker K, Kloss S, Heimann S, Goldmann A, Weber B, et al.
GMS Infect Dis
. 2019 Jan;
5:Doc02.
PMID: 30671324
To supplement the data collected in randomized clinical trials, the present study in patients with methicillin resistant (MRSA) pneumonia was conducted to explore the clinical effectiveness of linezolid and vancomycin...
4.
Basu A, Prabhu V, Dorr M, Golan Y, Dubberke E, Cornely O, et al.
Open Forum Infect Dis
. 2018 Nov;
5(11):ofy218.
PMID: 30460321
Background: Patients with recurrent infection (rCDI) are more likely to have a hospital readmission and spend increased time in inpatient settings compared with patients with primary CDI. MODIFY I and...
5.
Prabhu V, Cornely O, Golan Y, Dubberke E, Heimann S, Hanson M, et al.
Clin Infect Dis
. 2018 Jul;
65(7):1218-1221.
PMID: 30060024
NCT01241552 (MODIFY I) and NCT01513239 (MODIFY II).
6.
Heimann S, Biehl L, Vehreschild J, Franke B, Cornely O, Vehreschild M
Am J Infect Control
. 2018 Apr;
46(9):992-997.
PMID: 29661631
Background: A recent study reported a reduction in probable/definite central venous catheter (CVC)-related bloodstream infections (CRBSIs) in neutropenic high-risk patients using CVC dressings with a chlorhexidine-containing gel pad. Methods: Based...
7.
Zoran T, Sartori B, Sappl L, Aigner M, Sanchez-Reus F, Rezusta A, et al.
Front Microbiol
. 2018 Apr;
9:516.
PMID: 29643840
Invasive mold infections associated with species are a significant cause of mortality in immunocompromised patients. The most frequently occurring aetiological pathogens are members of the section followed by members of...
8.
Kron F, Kutsch N, Kostenko A, Dohle I, Glossmann J, Muller D, et al.
Eur J Haematol
. 2016 Oct;
98(2):169-176.
PMID: 27727474
Objectives: Treatment of chronic lymphocytic leukemia (CLL) is currently undergoing dramatic changes. We analyzed economic risks in hospitalized patients with CLL from a management perspective. Methods: One hundred and twelve...
9.
Heimann S, Vehreschild M, Cornely O, Franke B, von Bergwelt-Baildon M, Wisplinghoff H, et al.
Eur J Haematol
. 2014 Oct;
94(6):526-31.
PMID: 25310918
Background: Intravenous bridging strategies increase exposure of antifungal prophylaxis in high-risk hematological patients. The cost-effectiveness of such strategies has not been analyzed. Methods: A recent study compared the impact of...
10.
Heimann S, Cornely O, Vehreschild M, Glossmann J, Kochanek M, Kreuzer K, et al.
Mycoses
. 2013 Jun;
57(2):90-7.
PMID: 23790060
Prior clinical trials have demonstrated efficacy and effectiveness of posaconazole in the prophylaxis of invasive fungal diseases in high-risk patients. Controversy exists about the cost-effectiveness of this approach. We performed...